A Disease-Modifying Protein Therapeutic for the Treatment of COPD
Overview
Organization: National Heart, Lung, and Blood Institute
Start Date: 09/2019
End Date: Ongoing
Primary Goal: Goal 4: Increase and sustain research to better understand the prevention, pathogenesis, diagnosis, treatment, and management of COPD.
Secondary Goal(s):
Objective(s):
- Help expand, coordinate, and optimize COPD research efforts
Collaboration: Verra Therapeutics, LLC
Activity Type: Research
Activity Description
Chronic obstructive pulmonary disease (COPD) is a global, multi-phenotypic disease associated with lung damage from repeated external inflammatory insults such as smoke, vaping, forest fires, pollution, chemical exposure, and occupational hazards faced by 1st responders, the military, agricultural workers etc.. There are currently no treatments available for COPD patients that can halt or reverse the course of this disease. A protein has been identified which is responsible for key clinical outcomes in COPD and Verra Therapeutics aims to leverage this protein as a novel target to dramatically impact lung function in these patients.Audience
General Audience: Researchers
Focused Audience: n/a
Program Reach: National
Type of Area: N/A
Setting: Workplace
Cost and Funding Sources
It was funded through the National Heart, Lung and Blood Institute and funds to be allotted to grantees.Impact Analysis
Results of their programs are in progress.Advice or Lessons Learned
In process.Contact Information
National Heart, Lung, and Blood Institute
Program Analyst
Bethesda
Maryland